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Abstract
The	authors	describe	a	patient	who	presented	a	multifocal	motor	neuropathy	(MMN)	associated	with	a	
high	anti-ganglioside	antibody	(anti-GM1	and	anti-GD1)	 titer	at	 the	clinical	onset	of	a	B-cell	chronic	
lymphocytic	leukemia	(B-CLL).	Immunomodulation	(IVIg	plus	cyclosporine)	resulted	in	a	neurological	
improvement	and	reduced	anti-ganglioside	antibody	titers,	both	of	which	remained	stable	for	at	least	six	
years.	After	this	period,	the	patient	had	a	severe	relapse	of	the	neuropathy,	which	was	independent	of	the	
clinical	course	of	the	B-CLL.	Both	IVIg	and	cyclophosphamide	were	ineffective,	and	the	patient	became	
tetraplegic	 within	 six	months;	 in	 the	meantime,	 the	 patient	 displayed	 an	 increased	 antiganglioside	
antibody	titer.	Treatment	with	rituximab	(RTX),	which	is	designed	to	selectively	inhibit	B	cell	function,	
resulted	in	a	dramatic,	prompt	and	long-lasting	neurological	improvement	as	well	as	a	reduced	anti-
ganglioside	antibody	titer.	Although	there	are	no	previous	reports	of	MMN	in	patients	with	B-CLL,	the	
ef icacy	of	RTX	in	the	treatment	of	MMN	in	this	patient	may	be	considered	remarkable.	The	expansion	of	
B-cell	clones	may	be	a	prerequisite	for	RTX	effectiveness	in	MMN,	and	in	dysimmune	neuropathies	in	
general.
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Introduction
	 B-cell	 chronic	 lymphocytic	 leukemia,	 besides	 being	 a	malignant	 hematologic	 disease,	 is	 also	
considered	a	complex	immunologic	disorder	that	is	characterized	by	a	paradoxical	coexistence	of	an	
excess	of	autoimmune	phenomena	and	a	status	of	immune	de iciency	[1].	In	particular,	patients	with	CLL	
have	a	high	prevalence	of	autoimmune	hematologic	diseases,	caused	by	autoantibodies	produced	by	
clonal	or	polyclonal	B-cells	[2,	3],	and	progressively	develop	a	susceptibility	to	 infections	because	of	
severe	 hypogammaglobulinemia.	 These	 immune-mediated	 mechanisms	 have	 even	 been	 called	 into	
question	in	the	pathogenesis	of	peripheral	neuropathies	associated	with	CLL,	believed	to	be	related	to	the	
nerve	in iltration	of	malignant	cells	[4,	5].	
	 Rituxan	(Rituximab-RTX)	is	a	chimeric	(mouse/human)	monoclonal	antibody	that	eliminates	B	
lymphocytes	by	targeting	the	CD20	antigen	and	 inducing	apoptosis	and	complement-	and	antibody-
dependent	cytolysis	[6].	It	drastically	reduces	peripheral	CD19-positive	B	lymphocytes	and	prevents	the	
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formation	of	new	antibody-secreting	cells.	RTX	has	proved	to	be	effective	in	the	treatment	of	both	B-cell	
lymphoid	malignancies	and	B-cell-mediated	autoimmune	diseases	[3,	7,	8,	9].	Evidence	showing	that	B	
cells	and	autoantibodies	are	involved	in	the	pathogenesis	of	several	neurological	diseases	has	prompted	a	
therapeutic	 strategy	 based	 on	 the	 selective	 inhibition	 of	 B-cell	 function	 to	 treat	 a	 large	 number	 of	
neurological	dysimmune	conditions	[10].	In	this	regard,	several	reports	have	suggested	that	RTX	may	be	
bene icial	to	patients	with	multifocal	motor	neuropathy	(MMN)	[11,	12].	RTX	is,	however,	considered	an	
“add	on”	treatment	in	MMN	[13]	because	its	ef icacy	has	been	de ined	as	“quite	modest,	delayed	in	time,	
and	con ined	to	some	instances”	[14,	15]	and	it	could	not	show	a	long	term	response	[16].
	 This	 study	 documents	 a	 case	 of	MMN	 associated	with	 CLL	 (the	  irst	 in	 the	 literature	 to	 our	
knowledge)	in	which	RTX	induced	a	dramatic,	prompt	and	long-lasting	response.	
	 We	hypothesize	 that	 the	expansion	of	B-cell	 clones	may	be	a	prerequisite	 for	RTX	ef icacy	 in	
dysimmune	neuropathies.	Despite	being	anecdotal,	the	case	we	describe	lends	support	to	this	hypothesis.
Case	Report
	 A	 69-year-old	 patient	 with	 MMN	 and	 B-CLL	 was	 admitted	 to	 our	 department	 because	 his	
neurological	disease	had	worsened.	His	clinical	history	is	summarized	in	Figure	1.
	 He	had,	nine	years	before,	presented	a	painless,	progressive	weakness	in	the	right	hand,	followed,	
two	months	later,	by	weakness	in	the	left	hand	and	skin	eruptions	in	his	trunk,	arms	and	legs.	The	patient	
did	not	complain	of	sensory	symptoms.	Nerve	conduction	studies	(NCS)	had	shown	motor	conduction	
blocks	in	the	median	and	ulnar	nerves.	A	skin	biopsy	had	shown	vasculitic	urticaria,	while	a	hematological	
evaluation	had	revealed	a	B-cell	CLL.	Grade	4/5	weakness	(MRC)	in	right/left	hand	muscles	and	wrist	
extensors,	and	fasciculation	on	the	triceps	brachii	and	quadriceps	femoris,	without	sensory	impairment,	
had	been	detected	at	 the	neurological	examination.	The	cerebrospinal	  luid	had	been	unremarkable,	
while	the	blood	IgM	anti-GM1	antibody	titer	had	been	1:19.200	(ELISA	n.v.	<1:600).	A	diagnosis	of	MMN	
associated	with	CLL	had	been	made.	
	 Prednisone	 (50	 mg/day)	 and	 oral	 cyclophosphamide	 (CTX)	 (2mg/kg/day),	 had	 initially	
effectively	treated	the	CLL	and	vasculitic	urticaria;	however,	the	weakness	had	subsequently	worsened,	
involving	the	proximal	muscles	of	the	upper	limbs	and	left	quadriceps	(Rankin	scale:	2-3).	The	start	of	
intravenous	immunoglobulin	(IVIg)	(2g/Kg)	plus	cyclosporine	(CSA	3mg/kg/day)	had	been	followed	
both	by	an	improvement	in	strength	(Rankin	scale:	1)	and	a	decrease	in	anti-GM1	antibody	titer	(1:500)	
within	one	year.	During	the	following	six	years	both	the	hematological	and	the	neurological	picture	had	
remained	 stable,	 and	 both	 prednisone	 and	 cyclosporine	 had	 been	 tapered	 to	 5	 mg/day	 and	 1.5	
mg/kg/day	respectively.	In	September	2010,	the	patient's	muscle	strength	began	to	deteriorate	again	
and,	 one	month	 later,	 he	was	 admitted	 to	 our	 department.	 He	 showed	 a	 slight/moderate	 disability	
(Rankin	3-4).	The	neurological	examination	revealed	weakness	in	the	proximal	and	distal	muscles	of	the	
upper	and	lower	limbs	(MRC	sum-score	60/90:	left	deltoid	4/5,	right/left	biceps	and	extensor	digitorum	
4/5,	 right	 opponens	 pollicis	 and	 abductor	 pollicis	 brevis	 and	 right/left	 intrinsic	 muscle	 3/5,	 right	
ileopsoas	4/5,	right/left	gluteus	maximus	4/5,	tibialis	anterior	4/5,	extensor	allucis	longus	4/5,	extensor	
and	 lexor	digitorum	4/5)	and	atrophy	of	the	right/left	interosseous	and	right	thenar	muscles;	moreover,	
deep	tendon	re lexes	were	absent,	while	sensory	functions	were	normal.
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NCS	showed	low	distal	CMAP	amplitude,	motor	conduction	blocks,	motor	temporal	dispersion,	reduction	
of	motor	conduction	velocity	and	increased	F	wave	latency	in	the	right	ulnar	and	left	median	nerves	(table	
1	and	 igure	1).	Sensory	potential	amplitude	was	normal	in	right	ulnar	and	left	median	nerves,	and	slightly	
reduced	in	right	sural	nerves	was	(11	uv;	18	uv;	6	uv	respectively);		sensory	conduction	velocity		in	these	
nerves	was	normal	(51	m/s;	50	m/s;	42	m/s	respectively).	The	EMG	study	showed	neurogenic	damage	to	
the	proximal	and	distal	muscles	in	the	upper	and	lower	limbs.	
	 The	immunological	study	revealed	a	high	titer	of	IgM	anti-GM1	antibodies	(ELISA	231	Eu/ml.	
n.v.<25	Eu/ml)	and	anti-GD1b	IgM	antibodies	(41.7	Eu/ml.	n.v.<25	Eu/ml).	CSF	was	unremarkable	(cell	
3
1/mm 	protein	30	mg/dl,	glucose	61	mg/dl).	An	extensive	hematological	re-evaluation	con irmed	the	
diagnosis	of	B-cell	CLL	in	a	stable	phase.
	 A	sural	nerve	biopsy	showed	an	axonal	neuropathy	without	evidence	of	cell	in iltration.
	 Two	monthly	 courses	 of	 IVIg	 (2g/kg)	 and	 two	monthly	 courses	 of	 IVIg	 (2g/Kg)	 plus	 IV	 CTX	
2
(1g/m )	were	of	no	bene it.	In	the	meantime,	the	patient	had	become	unable	to	walk,	feed	and	dress	
himself	(Rankin	scale:	5;	MRC	sum-score	45/90).	
2
	 We	started	RTX	(375	mg/m ,	once	a	week	for	4	weeks)	plus	prednisone	(25	mg/day).	Within	one	
month,	 the	 patient	 showed	 an	 improvement	 in	muscle	 strength,	which	 progressed	 in	 the	 following	
months.	Three	RTX	courses	were	repeated,	respectively	at	6,	12	and	24	months.	All	the	RTX	infusions	
were	well	tolerated.	One	year	after	the	start	of	treatment,	the	patient	was	able	to	get	up	from	a	chair,	walk	
without	any	aid,	feed	and	dress	himself;	he	started	driving	and	participating	in	social	activities	again	
(Rankin	scale:	2).	IgM	anti-GM1	antibodies	had	dropped	to	127.7	Eu/ml.	The	electrophysiological	study	
showed	a	reduction	of	motor	conduction	blocks	(Table	1).	
	 At	present	the	patient	 is	under	clinical	observation,	and	is	being	treated	with	low	prednisone	
dosages	(5	mg/alternate	day).	He	continues	to	feel	well	and	leads	an	almost	normal	everyday	life.
Discussion
	 The	 clinical	 and	 electrophysiological	 characteristics	 in	 this	 case	 (i.e.	 motor,	 asymmetric	
neuropathy,	with	predominant	upper	limb	involvement	and	multifocal	motor	conduction	blocks)	ful il	
the	diagnostic	criteria	for	MMN	[17].	We	excluded	the	hypothesis	of	a	neoplastic	in iltration	of	the	nerves	
on	the	basis	of	the	course	the	neuropathy	(which	was	independent	of	the	course	of	the	CLL),	the	prevalent	
motor	involvement	and,	lastly,	the	results	of	both	the	nerve	biopsy	and	CSF	examination	[18].	On	the	other	
hand,	we	considered	the	hypothesis	of	an	immune-mediated	neuropathy	strongly	supported	by	the	high	
titer	 of	 both	 the	 anti-GM1	 IgM	 and	 anti-GD1b	 IgM,	 as	 well	 as	 by	 the	 good	 clinical	 response	 to	
immunomodulating	therapy.	Similarly,	the	effect	of	immunomodulating	treatment	upon	nerve	temporal	
dispersion	has	been	reported	in	one	or	more	nerve	segments	in	eight	of	nine	patients	with	MMN	[19].
	 Though	MMN	 has	 not	 previously	 been	 reported	 in	 patients	 with	 CLL,	 autoreactivity	 against	
different	types	of	gangliosides	has	been	observed	in	CLL	[20].	A	high	anti-GM1	IgM	antibody	titer,	while	
not	speci ic	to	MMN,	is	more	frequent	in	this	neuropathy	than	in	other	neuropathies	[21].	Moreover,	anti-
GD1b	IgM	antibodies	are	associated	with	an	immune-mediated	neuropathy	in	over	80%	of	patients	[17].	
IgM	reactivity	to	GD1b	has	been	associated	with	a	predominant	involvement	of	sensory	 ibers	[22,	23],	
which	may	explain	the	moderate	loss	of	sensory	nerve	 ibers	detected	in	the	sural	nerve	of	our	patient.	
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	 Since	 the	 introduction	of	 IVIg	 as	  irst-line	 treatment	 for	MMN,	 the	majority	of	MMN	patients	
bene it	from	this	treatment,	which	has	negligible	side	effects	[24].	However,	the	effectiveness	of	IVIg	in	
some	patients	may	decline	over	time	[25].	Cyclophosphamide,	if	necessary	combined	with	IVIg,	is	the	
main	 therapeutic	 alternative	 in	 such	 cases	 [26],	 but	 even	 this	may,	 as	 happened	 in	 our	 patient,	 be	
ineffective.	
	 Given	its	ability	to	markedly	deplete	B-cells,	RTX	has	been	exploited	to	disrupt	the	production	of	
antibodies	in	primary	autoimmune	cytopenias,	as	well	as	in	autoimmune	cytopenias	related	to	CLL	as	
well	 as	 other	 chronic	 lymphoproliferative	 diseases	 [7,	 9,	 27].	 Recent	 years	 have	witnessed	 growing	
interest	in	the	use	of	RTX	to	treat	autoimmune	neuropathies	related	to	IgM	antibody	anti-gangliosides	or	
glycolipids,	 in	which	autoreactive	B	cells	play	a	 central	 role.	The	ef icacy	of	RTX	however	 remains	a	
controversial	issue	[11,	12].	Rituximab	has	been	reported	to	be	effective	in	some	patients	with	MMN	[11,	
28],	as	well	as	in	small	groups	of	IVIg-resistant	MMN	patients	[14,	29].	Moreover,	RTX	was	effectively	used	
to	stabilize	a	patient	with	MMN	who	was	becoming	 increasingly	 less	 responsive	 to	 IVIg	 [14,	30].	By	
contrast,	RTX	was	unable	improve	the	clinical	symptoms	in	six	patients	with	an	IVIg-dependent	relapsing	
polyneuropathy	[31]	or	to	reduce	the	mean	total	IVIg	dosage	in	six	patient	with	MMN	[28].	However,	in	the	
same	study,	the	authors	stress	that	RTX	may	be	effective	in	isolated	cases,	depending	on	the	pathogenic	
role	of	CD20	lymphocytes.
	 Our	patient	showed	a	marked	and	long-lasting	clinical	improvement	following	treatment	with	
RTX,	 accompanied	by	 a	 signi icant	 reduction	 in	 anti-ganglioside	 IgM	antibodies.	Other	 authors	have	
described	a	CLL	patient	with	a	severe	axonal	neuropathy,	which	was	refractory	to	immunosuppressive	
therapies	but	improved	signi icantly	after	RTX	was	started	[3].	
	 We	hypothesize	that	the	marked	ef icacy	of	RTX	in	both	cases	was	conditioned	by	the	underlying	
B-CLL.	
	 The	role	of	leukemic	cells	in	the	pathogenesis	of	CLL-associated	autoimmune	disorders	has	yet	to	
be	fully	understood.	Indeed,	most	of	the	antibodies	involved	in	autoimmune	disorders	are	polyclonal	IgG,	
produced	 by	 non-clonal	 B	 cells,	while	 leukemic	 cells	 express	monoclonal	 IgM	 antibodies.	Moreover,	
immunosuppressive	 treatment	may	 inhibit	 autoimmune	manifestations,	without	 affecting	 the	 clonal	
expansion	of	CLL.	Finally,	leukemic	cells	often	express	antibodies	with	a	polyreactive	af inity	for	different	
antigens.	In	conclusion,	several	elements	point	to	a	predominantly	indirect	role	of	leukaemic	clones	in	the	
pathogenesis	of	CLL-associated	autoimmune	disorders	[7].	However,	RTX	may	act	either	on	clonal	or	
polyclonal	B-cells,	as	demonstrated	in	cold	agglutinine	disease	and	in	cryoglobulinemia,	both	of	which	are	
sustained	by	a	B-cell	clonal	expansion	[7,	32].	
	 Whatever	the	underlying	mechanism	of	the	immunological	disorder	is,	 it	seems	reasonable	to	
hypothesize	that	the	elimination	of	monoclonal	or	polyclonal	autoreactive	CD20+	lymphocyte	clones	may	
explain	 the	 therapeutic	 activity	 of	 RTX	 in	 this	 and	 other	 similar	 cases	 of	 Ig-M	 immune-mediated	
neuropathy,	as	well	as	in	other	neurological	disorders	and	autoimmune	cytopenias	associated	with	CLL	
[31,	33,	34].	Noteworthy,	the	comparison	of	IgM	anti-GM1	antibodies	from	patients	with	Guillain-Barré	
syndrome	 and	 MMN	 demonstrated	 a	 much	 restricted	 clonal	 diversity	 in	 the	 latter,	 suggesting	 that	
therapies	aimed	to	target	the	autoreactive	clones	may	be	useful	in	MMN	[35].
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2
	 The	dosage	interval	and	duration	of	therapy	in	our	case	was	the	recommended	dose	of	375	mg/m 	
IV	administered	weekly	for	4	weeks	[36],	and	subsequently	followed	by	repeated	courses	according	to	the	
patient's	clinical	condition.	The	therapy	was	well	tolerated,	with	no	adverse	effects	being	recorded	either	
during	or	after	treatment;	this	 inding	provides	further	proof	of	the	safety	of	this	drug	[37].
Figures
	 	 MRC;		 	 	 	 Rankin;		 	 	 Anti-GM1	IgM	Assay;
	 	 IVIG	course;		 	 	 Cyclophosphamide;		 	 Rituximab	 	
 
  
  
   
Figure	1:	Clinical	course	described	by	MRC	and	Rankin	Scales,	associated	with	the	anti-GM1	IgM	assays	done	
during	 the	 follow	 up	 visits	 and	 the	 treatments	 occurred	 (A);	 electrophysiological	  indings:	 note	Motor	 NCV	
increase	and	F	wave	latency	reduction,	especially	in	the	last	recording	in	January	2013	(B).
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